Revvity Announces Financial Results for the Third Quarter of 2024

Rhea-AI Summary

Revvity reported strong Q3 2024 financial results with revenue reaching $684 million, representing 2% reported and organic growth. GAAP EPS was $0.77, while adjusted EPS from continuing operations reached $1.28. The company's Diagnostics segment showed 6% growth with $383 million revenue, while Life Sciences recorded $301 million, a 2% decrease. Operating margins improved, with GAAP operating profit margin at 14.3% and adjusted operating profit margin at 28.3%. The company raised its full-year 2024 adjusted EPS guidance to $4.83-$4.87 and announced a new $1 billion share repurchase program.

Positive

• Revenue growth of 2% reaching $684 million
• GAAP EPS increased significantly from $0.08 to $0.77 YoY
• Adjusted EPS improved from $1.18 to $1.28
• Operating profit margin increased from 10.3% to 14.3%
• Diagnostics segment grew 6% to $383 million
• New $1 billion share repurchase program authorized
• Raised full-year 2024 adjusted EPS guidance

Negative

• Life Sciences segment revenue declined 2% to $301 million
• Life Sciences adjusted operating profit margin decreased from 37.1% to 34.2%
• Lowered full-year organic growth expectations to 0-1%

Insights

Financial Analyst

The Q3 results show mixed performance with some encouraging signals. Revenue growth of 2% both reported and organic indicates stability, while adjusted EPS of $1.28 represents an 8.5% improvement year-over-year. The Diagnostics segment is particularly strong, showing 5% organic growth and significant margin expansion to 26.5%.

The new $1 billion share repurchase authorization signals management's confidence in the company's financial position and commitment to shareholder returns. The raised full-year adjusted EPS guidance to $4.83-$4.87 is positive, though organic growth guidance of 0-1% suggests continued market challenges.

The margin improvement story is compelling, with adjusted operating profit margin expanding to 28.3% from 27.5% year-over-year, demonstrating effective cost management despite moderate top-line growth.

Market Research Analyst

The divergence between segments is noteworthy, with Life Sciences showing weakness (-3% organic decline) while Diagnostics demonstrates strength (5% organic growth). This split performance reflects broader market dynamics where diagnostic testing remains resilient while life sciences faces ongoing funding pressures.

The company's strategic positioning appears sound, with management's focus on innovation and partnerships potentially opening new growth avenues. The upcoming Investor Day could be a catalyst for the stock if management presents a compelling growth strategy and provides more clarity on market opportunities.

• Revenue of $684 million; 2% reported growth; 2% organic growth
• GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28
• Raises full year 2024 adjusted EPS guidance
• Authorizes new $1 billion share repurchase program
• To host Investor Day on November 21st

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024.

The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 million for the same period a year ago. GAAP operating profit margin from continuing operations was 14.3% as a percentage of revenue, as compared to 10.3% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.28, as compared to $1.18 in the same period a year ago. Adjusted revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. Adjusted operating income was $193 million, as compared to $185 million for the same period a year ago. Adjusted operating profit margin was 28.3% as a percentage of adjusted revenue, as compared to 27.5% in the same period a year ago.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

“We performed well during the third quarter with a return to positive revenue growth, strong margins, and another period of excellent cash flow,” said Prahlad Singh, president and chief executive officer of Revvity. “The impact we are having on our customers every day to help to advance science and healthcare is profound, and we are optimistic that we can increasingly make a meaningful difference around the world as we continue to innovate and partner with purpose.”

Share Repurchase Authorization

The Company’s Board of Directors has authorized a new two-year $1 billion share repurchase program which replaces the remainder of the existing program which was announced in May 2023.

Investor Day

The Company will host an Investor Day on Thursday, November 21^st beginning at 9:00 a.m. PT. To access the event, a live audio webcast will be available on the Investors section of the Company’s website.

Financial Overview by Reporting Segment

Life Sciences

• Third quarter 2024 revenue was $301 million, as compared to $308 million in the same period a year ago. Reported revenue decreased 2% and organic revenue decreased 3% as compared to the same period a year ago.

• Third quarter 2024 adjusted operating income was $103 million, as compared to $114 million in the same period a year ago. Adjusted operating profit margin was 34.2% as a percentage of adjusted revenue, as compared to 37.1% in the same period a year ago.

Diagnostics

• Third quarter 2024 revenue was $383 million, as compared to $363 million in the same period a year ago. Reported revenue increased 6% and organic revenue increased 5% as compared to the same period a year ago.

• Third quarter 2024 adjusted operating income was $101 million, as compared to $82 million in the same period a year ago. Adjusted operating profit margin was 26.5% as a percentage of adjusted revenue, as compared to 22.5% in the same period a year ago.

Full Year 2024 Guidance

For the full year 2024, the Company is updating its full year revenue guidance to $2.75-$2.77 billion to reflect recent changes in foreign currency exchange rates and assumes 0% to 1% organic growth. The Company is also raising its adjusted EPS guidance to a range of $4.83 to $4.87.

Guidance for the full year 2024 for organic growth and adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its third quarter 2024 results and its outlook for business trends during a webcast on November 4, 2024, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED INCOME STATEMENTS
		Three Months Ended								Nine Months Ended
(In thousands, except per share data)		September 29, 2024				October 1, 2023				September 29, 2024				October 1, 2023
Revenue		$	684,049			$	670,739			$	2,025,654			$	2,054,670
Cost of revenue			299,233				298,223				900,285				898,457
Selling, general and administrative expenses			237,521				250,249				749,742				765,828
Research and development expenses			49,144				53,039				147,636				166,982
Operating income from continuing operations			98,151				69,228				227,991				223,403
Interest income			(22,764	)			(23,450	)			(63,362	)			(53,768	)
Interest expense			24,383				25,486				73,497				74,231
Change in fair value of financial securities			(7,004	)			13,587				(13,975	)			12,842
Other expense, net			3,179				3,002				10,263				38,501
Income from continuing operations, before income taxes			100,357				50,603				221,568				151,597
Provision for income taxes			6,971				18,134				26,880				35,661
Income from continuing operations			93,386				32,469				194,688				115,936
Income (loss) from discontinued operations			981				(22,972	)			(18,948	)			498,595
Net income		$	94,367			$	9,497			$	175,740			$	614,531
Diluted earnings per share:
Income from continuing operations		$	0.76			$	0.26			$	1.58			$	0.93
Income (loss) from discontinued operations			0.01				(0.18	)			(0.15	)			3.98
Net income		$	0.77			$	0.08			$	1.42			$	4.90
Weighted average diluted shares of common stock outstanding			123,026				124,203				123,336				125,335
ABOVE PREPARED IN ACCORDANCE WITH GAAP
Additional supplemental information(1):
(per share, continuing operations)
GAAP EPS from continuing operations		$	0.76			$	0.26			$	1.58			$	0.93
Amortization of intangible assets			0.73				0.73				2.20				2.20
Debt extinguishment costs			-				(0.00	)			-				(0.03	)
Purchase accounting adjustments			0.00				0.01				0.06				0.02
Acquisition and divestiture-related costs			0.02				0.09				0.13				0.63
Change in fair value of financial securities			(0.06	)			0.11				(0.11	)			0.10
Significant litigation matters and settlements			0.01				-				0.06				-
Significant environmental matters			-				-				-				0.01
Restructuring and other, net			(0.00	)			0.09				0.18				0.13
Tax on above items			(0.18	)			(0.25	)			(0.62	)			(0.73	)
Significant tax items			-				0.14				-				0.13
Adjusted EPS from continuing operations		$	1.28			$	1.18			$	3.47			$	3.39
(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries REVENUE AND OPERATING INCOME (LOSS)
		Three Months Ended								Nine Months Ended
(In thousands, except percentages)		September 29, 2024				October 1, 2023				September 29, 2024				October 1, 2023
Adjusted revenue and operating income
Reported revenue		$	684,049			$	670,739			$	2,025,654			$	2,054,670
Revenue purchase accounting adjustments			205				206				621				618
Adjusted revenue		$	684,254			$	670,945			$	2,026,275			$	2,055,288
Reported operating income from continuing operations		$	98,151			$	69,228			$	227,991			$	223,403
OP%			14.3	%			10.3	%			11.3	%			10.9	%
Amortization of intangible assets			89,642				90,920				271,500				275,489
Purchase accounting adjustments			103				1,080				7,348				3,057
Acquisition and divestiture-related costs			4,874				12,550				22,115				59,080
Significant litigation matters and settlements			810				—				7,086				—
Significant environmental matters			—				—				—				1,132
Restructuring and other, net			(82	)			10,832				22,119				15,936
Adjusted operating income		$	193,498			$	184,610			$	558,159			$	578,097
OP%			28.3	%			27.5	%			27.5	%			28.1	%
Segment revenue and segment operating income
Life Sciences		$	300,921			$	307,855			$	917,805			$	972,649
Diagnostics			383,333				363,090				1,108,470				1,082,639
Revenue purchase accounting adjustments			(205	)			(206	)			(621	)			(618	)
Reported revenue		$	684,049			$	670,739			$	2,025,654			$	2,054,670
Life Sciences		$	102,979			$	114,192			$	317,105			$	371,410
			34.2	%			37.1	%			34.6	%			38.2	%
Diagnostics			101,434				81,741				274,779				241,414
			26.5	%			22.5	%			24.8	%			22.3	%
Corporate			(10,915	)			(11,323	)			(33,725	)			(34,727	)
Subtotal reportable segments operating income			193,498				184,610				558,159				578,097
Amortization of intangible assets			(89,642	)			(90,920	)			(271,500	)			(275,489	)
Purchase accounting adjustments			(103	)			(1,080	)			(7,348	)			(3,057	)
Acquisition and divestiture-related costs			(4,874	)			(12,550	)			(22,115	)			(59,080	)
Significant litigation matters and settlements			(810	)			—				(7,086	)			—
Significant environmental matters			—				—				—				(1,132	)
Restructuring and other, net			82				(10,832	)			(22,119	)			(15,936	)
Reported operating income from continuing operations		$	98,151			$	69,228			$	227,991			$	223,403
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)	September 29, 2024			December 31, 2023
Current assets:
Cash and cash equivalents	$	1,229,778		$	913,163
Marketable securities		—			689,916
Accounts receivable, net		602,141			632,811
Inventories, net		404,570			428,062
Other current assets		211,917			337,139
Total current assets		2,448,406			3,001,091
Property, plant and equipment, net		517,932			509,654
Operating lease right-of-use assets, net		149,305			155,083
Intangible assets, net		2,763,211			3,022,321
Goodwill		6,558,660			6,533,550
Other assets, net		332,223			342,966
Total assets	$	12,769,737		$	13,564,665
Current liabilities:
Current portion of long-term debt	$	1,045		$	721,872
Accounts payable		176,407			204,121
Accrued expenses and other current liabilities		510,488			524,470
Total current liabilities		687,940			1,450,463
Long-term debt		3,185,699			3,177,770
Long-term liabilities		845,998			930,946
Operating lease liabilities		128,399			132,747
Total liabilities		4,848,036			5,691,926
Total stockholders' equity		7,921,701			7,872,739
Total liabilities and stockholders' equity	$	12,769,737		$	13,564,665
PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF CASH FLOWS
	Three Months Ended								Nine Months Ended
(In thousands)	September 29, 2024				October 1, 2023				September 29, 2024				October 1, 2023
Operating activities:
Net income	$	94,367			$	9,497			$	175,740			$	614,531
(Income) loss from discontinued operations, net of income taxes		(981	)			22,972				18,948				(498,595	)
Income from continuing operations		93,386				32,469				194,688				115,936
Adjustments to reconcile income from continuing operations to net cash provided by (used in) continuing operations:
Stock-based compensation		10,538				10,703				32,756				34,229
Restructuring and other, net		(82	)			10,832				22,119				15,936
Depreciation and amortization		107,670				108,263				322,816				326,201
Change in fair value of contingent consideration		(343	)			633				6,006				1,718
Amortization of deferred debt financing costs and accretion of discounts		1,542				1,982				5,051				5,800
Change in fair value of financial securities		(7,004	)			13,587				(13,975	)			12,842
Debt extinguishment gain		—				(77	)			—				(3,422	)
Unrealized foreign exchange (gain) loss		(206	)			—				(1,063	)			23,679
Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:
Accounts receivable, net		5,097				(20,697	)			33,291				(30,913	)
Inventories, net		9,566				(8,059	)			26,817				(34,834	)
Accounts payable		(1,808	)			(36,169	)			(24,782	)			(85,394	)
Accrued expenses and other		(61,342	)			(82,710	)			(114,236	)			(322,995	)
Net cash provided by operating activities of continuing operations		157,014				30,757				489,488				58,783
Net cash used in operating activities of discontinued operations		(9,129	)			(64,242	)			(35,419	)			(164,124	)
Net cash provided by (used in) operating activities		147,885				(33,485	)			454,069				(105,341	)
Investing activities:
Capital expenditures		(22,319	)			(22,357	)			(62,194	)			(57,252	)
Purchases of investments and notes receivables		—				(1,000	)			(4,337	)			(6,000	)
Proceeds from notes receivables		2,500				—				2,500				—
Purchases of U.S. Treasury Securities		—				—				—				(831,219	)
Proceeds from U.S. Treasury Securities		710,000				450,000				710,000				550,000
Proceeds from disposition of businesses and assets		—				153				—				153
Cash paid for acquisitions, net of cash acquired		—				(1,400	)			—				(2,086	)
Net cash provided by (used in) investing activities of continuing operations		690,181				425,396				645,969				(346,404	)
Net cash provided by investing activities of discontinued operations		—				9,473				147,522				2,074,734
Net cash provided by investing activities		690,181				434,869				793,491				1,728,330
Financing Activities:
Payments of debt financing costs		—				—				—				(15	)
Payments of senior unsecured notes		(711,479	)			(467,138	)			(711,479	)			(517,973	)
Net proceeds (payments) on other credit facilities		429				(13	)			(10,771	)			7,218
Payments for acquisition-related contingent consideration		(83	)			—				(8,832	)			(10,117	)
Proceeds from issuance of common stock under stock plans		141				506				6,173				3,721
Purchases of common stock		(154,112	)			(110,715	)			(184,421	)			(384,014	)
Dividends paid		(8,633	)			(8,689	)			(25,915	)			(26,327	)
Net cash used in financing activities		(873,737	)			(586,049	)			(935,245	)			(927,507	)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash		17,051				(10,699	)			4,120				(28,270	)
Net (decrease) increase in cash, cash equivalents, and restricted cash		(18,620	)			(195,364	)			316,435				667,212
Cash, cash equivalents, and restricted cash at beginning of period		1,249,428				1,333,322				914,373				470,746
Cash, cash equivalents, and restricted cash at end of period	$	1,230,808			$	1,137,958			$	1,230,808			$	1,137,958
Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents	$	1,229,778			$	1,136,721			$	1,229,778			$	1,136,721
Restricted cash included in other current assets		1,030				1,237				1,030				1,237
Total cash, cash equivalents and restricted cash	$	1,230,808			$	1,137,958			$	1,230,808			$	1,137,958
PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
			Continuing Operations
			Three Months Ended
			September 29, 2024
Organic revenue growth:
Reported revenue growth from continuing operations			2%
Less: effect of foreign exchange rates			0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			2%
			Life Sciences
			Three Months Ended
			September 29, 2024
Organic revenue growth:
Reported revenue growth from continuing operations			-2%
Less: effect of foreign exchange rates			0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			-3%
			Diagnostics
			Three Months Ended
			September 29, 2024
Organic revenue growth:
Reported revenue growth from continuing operations			6%
Less: effect of foreign exchange rates			0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			5%
(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
			Continuing Operations
			Twelve Months Ended
			December 29, 2024
			Projected
Organic revenue growth:
Reported revenue growth from continuing operations			0% - 1%
Less: effect of foreign exchange rates			0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			0% - 1%
(1) amounts may not sum due to rounding

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” or “organic growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

We use the term “adjusted operating income” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” and “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term “free cash flow” to refer net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).

We use the term “adjusted net income,” to refer to GAAP income from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “adjusted earnings per share from continuing operations” or “adjusted earnings per share,” or “adjusted EPS," to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

• Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

• Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.

• Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.

• Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.

• Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.

• Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

• Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.

• Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.

• Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

• Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

• Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

• Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.

• Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.

• Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104029574/en/

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com



Media Contact:

Fara Goldberg (781) 663-5699

fara.goldberg@revvity.com

Source: Revvity

FAQ

What was Revvity's (RVTY) revenue in Q3 2024?

Revvity reported revenue of $684 million in Q3 2024, representing a 2% growth both reported and organic compared to the same period last year.

How much did Revvity's (RVTY) EPS grow in Q3 2024?

Revvity's GAAP EPS grew from $0.08 to $0.77 year-over-year, while adjusted EPS increased from $1.18 to $1.28.

What is Revvity's (RVTY) new share repurchase program?

Revvity's Board authorized a new two-year $1 billion share repurchase program, replacing the remainder of the existing program announced in May 2023.

What is Revvity's (RVTY) updated guidance for full-year 2024?

Revvity updated its full-year 2024 revenue guidance to $2.75-$2.77 billion with 0-1% organic growth, and raised adjusted EPS guidance to $4.83-$4.87.